Literature DB >> 19023518

Analysis of OCT4 expression in an extended panel of human tumor cell lines from multiple entities and in human mesenchymal stem cells.

T Mueller1, J Luetzkendorf, K Nerger, H-J Schmoll, L P Mueller.   

Abstract

OCT4 is considered a main regulator of embryonic stem cell pluripotency and self renewal capacity. It was shown that relevant OCT4 expression only occurs in cells of embryonic pluripotent nature. However, several recent publications claimed to have demonstrated OCT4 expression in human somatic tumor cells, human adult stem or progenitor cells and differentiated cells.We analysed 42 human tumor cell lines from 13 entities and human bone marrow-derived mesenchymal stem cells (MSC). To validate OCT4 expression we used germ cell tumor (GCT) cell lines, derived xenografts and GCT samples. Analysis by RT-PCR, western blotting, immunocytochemistry and immunohistochemistry was performed. With exception of typical embryonal carcinoma cells, we did not observe reliable OCT4 expression in somatic tumor cell lines and MSC. We suggest that a high level of expression of the OCT4 protein together with its nuclear localization still remains a reliable and definitive feature of cells with embryonic pluripotent nature.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19023518     DOI: 10.1007/s00018-008-8623-z

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  17 in total

Review 1.  [Therapeutic application of mesenchymal stromal cells in autoimmune disease: rationale and initial clinical experience].

Authors:  G Keysser; L Müller; M Schendel; H-J Schmoll
Journal:  Z Rheumatol       Date:  2009-05       Impact factor: 1.372

2.  Human trabecular meshwork cells exhibit several characteristics of, but are distinct from, adipose-derived mesenchymal stem cells.

Authors:  Joshua T Morgan; Joshua A Wood; Naomi J Walker; Vijay Krishna Raghunathan; Dori L Borjesson; Christopher J Murphy; Paul Russell
Journal:  J Ocul Pharmacol Ther       Date:  2014-01-23       Impact factor: 2.671

3.  OCT4 pseudogenes present in human leukemia cells.

Authors:  Xiaoping Guo; Yongmin Tang
Journal:  Clin Exp Med       Date:  2011-11-16       Impact factor: 3.984

4.  Upregulation of Oct-4 isoforms in pulmonary artery smooth muscle cells from patients with pulmonary arterial hypertension.

Authors:  Amy L Firth; Weijuan Yao; Carmelle V Remillard; Aiko Ogawa; Jason X-J Yuan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-02-05       Impact factor: 5.464

5.  Human haematopoietic stem cells express Oct4 pseudogenes and lack the ability to initiate Oct4 promoter-driven gene expression.

Authors:  Zoe Redshaw; Alastair J Strain
Journal:  J Negat Results Biomed       Date:  2010-03-31

Review 6.  Concise review: isoforms of OCT4 contribute to the confusing diversity in stem cell biology.

Authors:  Xia Wang; Jianwu Dai
Journal:  Stem Cells       Date:  2010-05       Impact factor: 6.277

Review 7.  The emerging roles of Oct4 in tumor-initiating cells.

Authors:  Ying-Jie Wang; Meenhard Herlyn
Journal:  Am J Physiol Cell Physiol       Date:  2015-10-07       Impact factor: 4.249

Review 8.  Octamer-binding transcription factors: genomics and functions.

Authors:  Feng-Qi Zhao
Journal:  Front Biosci (Landmark Ed)       Date:  2013-06-01

9.  Cyclin D1 affects epithelial-mesenchymal transition in epithelial ovarian cancer stem cell-like cells.

Authors:  Jie Jiao; Lu Huang; Feng Ye; Minfeng Shi; Xiaodong Cheng; Xinyu Wang; Dongxiao Hu; Xing Xie; Weiguo Lu
Journal:  Onco Targets Ther       Date:  2013-06-20       Impact factor: 4.147

10.  Aberrant promoter methylation and expression of UTF1 during cervical carcinogenesis.

Authors:  Samuel Guenin; Mustapha Mouallif; Rachel Deplus; Xavier Lampe; Nathalie Krusy; Emilie Calonne; Katty Delbecque; Frederic Kridelka; François Fuks; My Mustapha Ennaji; Philippe Delvenne
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.